← Patent-cliff monitor small molecule VORANIGO VORASIDENIB
Loss of exclusivity January 2039 latest FDA-listed patent expiry
Company SERVIER PHARMACEUTICALS LLC
Drug detail Brand name VORANIGO Active ingredient VORASIDENIB Strength 10MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval August 2024 Marketing status RX
Listed patents Patent Expires Type 11345677 January 2039 substance, product 11844758 December 2035 use U-3977 12433895 July 2034 use U-4286 10172864 July 2034 substance, product 9579324 July 2034 substance
Regulatory exclusivity Code Expires ODE-491 August 2031 NCE August 2029
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.